Scholarlink

Chimeric antigen receptor (CAR)-T cell therapy has emerged as a groundbreaking immunotherapeutic approach to cancer treatment. However, despite its remarkable results, challenges persist, such as manufacturing complexity, side effects, and cost. Allogeneic therapies offer potential solutions to these challenges by enhancing accessibility, reducing cost, and increasing scalability. Due to their innate cytotoxicity and reduced risks of side effects to the patients, natural killer cells are an up-and-coming option for allogeneic CAR therapy. The NK-92 cell line use allows large-scale expansion suitable for clinical grade applications, providing a uniform and highly cytotoxic source. Nevertheless, gene delivery using viral vectors is still an obstacle related to CAR-NK therapies due to their natural antiviral activity. Thus, the present protocol offers an efficient approach for CAR-NK-92 cell generation via lentiviral transduction, thereby advancing the potential of this promising cancer therapy.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineered CAR-NK Cells for Cancer Immunotherapy: Lentiviral-Based CAR Transduction of NK-92 Cells

  • 实验方案

  • 发表日期：

    2025年

查看全文
  • Dayane Schmidt,
  • Mariane Cariati Tirapelle,
  • Sima Ebrahimabadi,
  • Alison Felipe Bordini Biggi,
  • Matheus Henrique dos Santos,
  • Mara Elisama da Silva-Januário,
  • Virginia Picanço e Castro

摘要

Chimeric antigen receptor (CAR)-T cell therapy has emerged as a groundbreaking immunotherapeutic approach to cancer treatment. However, despite its remarkable results, challenges persist, such as manufacturing complexity, side effects, and cost. Allogeneic therapies offer potential solutions to these challenges by enhancing accessibility, reducing cost, and increasing scalability. Due to their innate cytotoxicity and reduced risks of side effects to the patients, natural killer cells are an up-and-coming option for allogeneic CAR therapy. The NK-92 cell line use allows large-scale expansion suitable for clinical grade applications, providing a uniform and highly cytotoxic source. Nevertheless, gene delivery using viral vectors is still an obstacle related to CAR-NK therapies due to their natural antiviral activity. Thus, the present protocol offers an efficient approach for CAR-NK-92 cell generation via lentiviral transduction, thereby advancing the potential of this promising cancer therapy.